ANNE TSAO to Neoadjuvant Therapy
This is a "connection" page, showing publications ANNE TSAO has written about Neoadjuvant Therapy.
Connection Strength
0.472
-
Current readings: Window-of-opportunity trials for thoracic malignancies. Semin Thorac Cardiovasc Surg. 2014; 26(4):323-30.
Score: 0.186
-
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2024 Oct 23; 12(10).
Score: 0.092
-
Use of Immune Checkpoint Inhibitors in Mesothelioma. Curr Treat Options Oncol. 2019 02 14; 20(2):18.
Score: 0.062
-
Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma. Clin Lung Cancer. 2009 Jan; 10(1):36-41.
Score: 0.031
-
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604.
Score: 0.021
-
Tumor thickness in mesothelioma predicts differential response to neoadjuvant therapy and survival. J Thorac Cardiovasc Surg. 2023 08; 166(2):362-371.e9.
Score: 0.020
-
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022 11; 164(5):1327-1337.
Score: 0.019
-
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
Score: 0.018
-
A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536.
Score: 0.017
-
Radiotherapy in malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2009 Oct 01; 75(2):326-37.
Score: 0.008